CERVARIX is a HPV2 vaccine indicated for the prevention of cervical cancer, cervical intraepithelial neoplasia (CIN) and adenocarcinoma and cervical intraepithelial neoplasia diseases caused by oncogenic human papillomavirus (HPV) types 16 and 18. CERVARIX is approved for use in females 9 through 25 years of age. CERVARIX does not provide protection against disease due to all HPV types. CERVARIX has not been demonstrated to provide protection against disease from vaccine and non-vaccine HPV types to which a woman has previously been exposed through sexual activity.
Immunization with CERVARIX consists of 3 doses of 0.5-mL each, by intramuscular injection according to the following schedule: 0, 1, and 6 months. The preferred site of administration is the deltoid region of the upper arm. For more details see immunization schedule and footnotes for HPV.
For latest IAP updates see revised immunization schedule.
Bivalent Human Papilloma Virus (Types 16 and 18) Recombinant virus like particle vaccine
Severe allergic reactions (e.g., anaphylaxis) to any component of CERVARIX
|Country of Manufacture|